openPR Logo
Press release

Restless Legs Syndrome Treatment Market is Projected to Exhibit Growth at an Increased Rate with the Development of New Drugs which Promise Higher Efficiency and Minimum Side Effects

04-27-2017 04:14 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Restless Legs Syndrome Treatment Market is Projected to Exhibit

Global Restless Legs Syndrome Treatment Market: Overview

Restless legs syndrome, also called Willis-Ekbom disease, is a neurological disorder. It triggers an urge in patients to move their legs. Because the syndrome usually occurs during sleep, it is also considered a type of sleep disorder. People suffering from restless legs syndrome often feel an overwhelming desire to rigorously move their legs, the intensity and frequency of which leads to unpleasant pain in their limbs. This also disturbs their sleep patterns, affecting their health adversely. The condition usually aggravates at night.

Browse the Complete Market Details at: http://www.transparencymarketresearch.com/restless-legs-syndrome-market.html

Higher prevalence of restless legs syndrome is noted in women than in men. RLS can affect people of all ages but is mostly observed in middle-aged and elderly people. The most common symptoms of RLS include uncomfortable itching and pain in the legs that may cause a disruption in the sleep pattern and ultimately affect a patient’s quality of life. Despite its increasing prevalence, the precise cause of RLS is not yet known. Nevertheless, with extensive investigations being conducted in the field, the RLS market is expected to gain momentum in the near future. As of now, experts attribute the increasing incidence of the disease to genetic factors and instabilities in the dopaminergic balance.

While researchers are yet to discover a specific cure for the disorder, drugs presently available in the market ensure symptomatic treatment. They help in relieving the uneasiness commonly experienced in the disorder. The report studies the prospects for the global restless legs syndrome treatment market in the forthcoming years. The impact of research and development activities on the market’s future outlook is examined in the report in detail. It also presents insights into the various social and economic factors that will influence the market’s growth trajectory between 2016 and 2024.

Global Restless Legs Syndrome Treatment Market: Opportunities and Market Segmentation

Restless legs syndrome causes uneasiness in patients and is also associated with other health issues such as dizziness, headaches, drowsiness, flatulence, dry mouth, and nausea. Patients suffering from restless legs syndrome may also suffer from psychiatric disorders such as depression and a decreased libido. Apart from these, labyrinthitis and other ear disorders, fatigue, irritability, peripheral edema, and nutritional and metabolism disorders indicated by weight gain or increased appetite are also related to the syndrome.

The treatment of restless legs syndrome is still a relatively untapped space. The market is projected to exhibit growth at an increased rate with the development of new drugs, which promise higher efficiency and minimum side effects.

Based on product type, the global restless legs syndrome treatment market can be segmented into Neupro/Leganto, Mirapex/Sifrol/Mirapexin, HORIZANT/Regnite, and Requip. Restless legs syndrome treatment can be segmented into pharmacological and nonpharmacological.

Global Restless Legs Syndrome Treatment Market: Competitive Insights

In order to study the competitive landscape prevailing in the market, the report profiles companies such as GlaxoSmithKline plc., Kyowa Hakko Kirin Co., Boehringer Ingelheim GmbH, Jazz Pharmaceuticals, Inc., and Manhattan Pharmaceuticals. The strengths and weaknesses of the companies are weighed out in the report using SWOT analysis. The analysis also helps the report gauge the threats and opportunities that these companies could face in the near future.

Get the Sample PDF Report Containing the Upcoming Analysis for this Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12506

The report offers a complete databank about the global restless legs syndrome treatment market by providing in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information regarding every facet of the market.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Restless Legs Syndrome Treatment Market is Projected to Exhibit Growth at an Increased Rate with the Development of New Drugs which Promise Higher Efficiency and Minimum Side Effects here

News-ID: 517724 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Restless

Restless Legs Syndrome - Drug Pipeline Landscape, 2022
Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move one's legs. The exact cause of RLS is unknown, but it is thought to be associated with a dysfunction in the brain's dopamine system. This system is responsible for regulating movement and is also involved in the feeling of pleasure and reward. RLS is thought to be caused by a combination of genetic and environmental
Restless Legs Syndrome - Pipeline Review, 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the
Restless Legs Syndrome – Pipeline Share, Trends and Research Report (2017)
Albany, New York, March 15, 2017: Market Research Hub has recently announced the report on “Restless Legs Syndrome”. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome Pipeline Review, H1 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape. Request a Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1021063 Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the
Restless Legs Syndrome - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Restless Legs Syndrome - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder
Global Restless Legs Syndrome Consumption 2016 Market Research Report
ReportBazzar has announced a new report titled "Global Restless Legs Syndrome Consumption 2016 Market Research Report" To their offerings Browse Report Summary with TOC: http://www.reportbazzar.com/product/global-restless-legs-syndrome-consumption-2016-market-research-report/ The Global Restless Legs Syndrome Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Restless Legs Syndrome market. First, the report provides a basic overview of the Restless Legs Syndrome industry including definitions, classifications, applications and industry chain structure. And
Studies Link Restless Leg Syndrome and Insomnia to Magnesium Deficiency
Restless leg syndrome (RLS) is a form of insomnia characterized by an overwhelming urge to move the legs when they are at rest, especially during sleep. RLS affects about 10% of the people in the U.S. It runs in families and may have a genetic component. Recent research has found that people with restless leg syndrome are deficient in the mineral magnesium. According to the National Sleep Foundation, almost